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Abstract
Primary immunodeficiency diseases are chronic dis-
orders which are characterized by increased sensi-
tivity of the organism to infections because one or 
more parts of the body’s immune system is missing. 
Immunoglobulins are normal components of the hu-
man body with the main role in the immune defense. 
Children with primary immunodeficiency have little 
or no antibodies and lifelong routine replacement 
therapy is the only effective treatment which repre-
sents the gold standard in treatment. The purpose 
of this therapy is to prevent acute infections and re-
duce complications resulting from infection. A nurse 
equipped with knowledge and competences is an 
indispensable link in the safe and quality adminis-
tration of immunotherapy and in providing immedi-
ate psychological support to the child and the entire 
family. Nurses administer 90% of all intravenous im-
munoglobulin therapy transfusions according to the 
provisions of the physician.
The paper presents findings of a research study into 
nurse´s perceptions about the Immunoglobulin re-
placement therapy. This paper represents nursing 
guidelines before, during and after administering 
intravenous immunoglobulin in children with primary 
immunodeficiency disease.
Intravenous Immunoglobulin 
Replacement Therapy in Children  
with Primary Immunodeficiency 
Diseases: A Nurse's Guide
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at times mask many of the common symptoms and 
signs of infection (4). Due to the weakness of the 
immune system, changes in skin and mucous mem-
branes are commonly reported (e.g., eczema, warts, 
abscesses, pyoderma, oral and esophageal ulcera-
tion, and periodontitis). After thoroughly reviewing 
a patient’s medical history, undergoing a physical 
examination and taking blood tests, a final confirma-
tion of diagnosis is possible based on the results of 
immunological and genetic tests.
Given that recurrent infections are the main problem, 
several specific types of therapy are available for 
children with a primary immunodeficiency disease 
where such therapies strengthen immunity. One of 
these is replacement therapy for missing compo-
nents of the immune system. Replacement therapy 
can also include IV immunoglobulin and hematopoi-
etic stem cell transplantation.
IVIG therapy
Intravenous immunoglobulin therapy is a human 
antibody solution which has been used as a medi-
cal treatment for decades. However, its use has in-
creased over the last few years due to good respons-
es in the body when treating various diseases. As 
was the case with prophylaxis for measles, hepatitis 
and polio, the concentration of human IVIG began 
to be used as early as World War II. Most often, the 
therapy was administered only subcutaneously and 
intramuscularly (5). 
Immunoglobulin preparations are extracted from the 
serum of 1,000-60,000 voluntary healthy donors, a 
combination of several thousand donors depending 
on the manufacturer (6,7) who go through screen-
ing for possible infections such as hepatitis B, C and 
HIV. The WHO has published minimum standards for 
manufacturing IVIG preparations (7): 
• IVIG should be extracted from a pool of a least 
1000 individual donors
• IVIG should contain as little IgA as possible
• IVIG should be free from preservatives or sta-
bilizers that might accumulate in vivo
The preparations contain highly purified (> 95 %) 
polyvalent IgG (8).
Immunoglobulin G is prepared from the fractionation 
of a large amount of normal human plasma and con-
tains a wide spectrum of antibodies (9).
Introduction
Primary or congenital immunodeficiencies (PID) are 
caused by genetic defects which in turn interrupt the 
maturation and functioning of various components 
of the immune system. Immunodeficiency may be 
independent or linked to a syndrome. The diseases 
are usually already present in infancy and childhood 
and are manifested as common (recurrent) or unusual 
infections. They are characterized by a lack of anti-
bodies (agammaglobulinemia), antibody deficiencies 
(hypoglobulinemia) and a lack of specific subclasses 
of immunoglobulins (normoglobulinemia). These chil-
dren are immunocompromised against all opportun-
istic infections and are also prone to allergies and 
autoimmune diseases. 
More than 250 PID entities have been defined to 
date, with the number rapidly evolving (1,2).
This paper will review certain anecdotal evidence for 
indications and administration of intravenous immu-
noglobulin (IVIG). In additional to the review in the 
table further on, the adverse effects of IVIG therapy 
and interventions by nursing personnel is addressed. 
The goal of IVIG infusion in nursing practice should 
be to deliver therapy safely and effectively. A nurs-
ing policy should be in place for treatment and man-
agement of all adverse reactions. 
Immunodeficiency
Immunodeficiencies should be suspected as the 
cause of recurrent infections when atypical signs 
and symptoms occur (recurrent otitis media after 
antibiotic treatment, chronic recurrent rhinosinusitis, 
persistent pneumonia after adequate therapy with 
antibiotics), when usually accompanied by complica-
tions and resistance to treatment, or in the case of 
infections caused by unusual microorganisms.
Infections of the upper and lower respiratory tract 
are the most commonly reported symptoms (sinusi-
tis, bronchitis, pneumonia), as well as gastroenteritis, 
but serious bacterial infections such as meningitis 
may also occur. Immunodeficiency should be sus-
pected in infants or small children with chronic di-
arrhea and growth delay, especially when diarrhea 
is caused by unusual viruses such as, for example, 
adenoviruses (3). Frequent use of antibiotics may 
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Mild reactions include dizziness, headache and flash-
es of light in vision. Other symptoms such as fever, 
nausea, vomiting, joint pain and moderate back or 
hip pain may also occur (15,16). Moderate reactions 
include strong headaches that do not stop after the 
administration of analgesics, rashes with or without 
itching, and the exacerbation or recurred appearance 
of mild reactions. The most common delayed system-
ic reaction is persistent headache (17). 
Flu-like symptoms are the most frequent adverse ef-
fects (18). One retrospective study showed that 14 
of 16 (87.5%) patients developed flu-like symptoms 
during immunoglobulin administration (19).
As with other blood products, administration of im-
munoglobulins may lead to serious complications 
such as hemolytic anemia, anaphylactic reactions 
(13), renal insufficiency, aseptic meningitis (11, 20) 
and exacerbation of all moderate reactions. Fortu-
nately, severe side effects are rare (15,21). Recog-
nizing and preventing late reactions in a timely man-
ner requires placing the child under observation for 
at least 24 hours. Constant hydration and taking of 
fluids is necessary for maintaining normal renal func-
tion. All symptoms and signs of allergic reaction must 
be documented.
Some of the necessary nursing procedures are given 
in Table 2.
It may take several infusions to develop a tolerable 
specific IVIG regimen for each patient. While all Ig prod-
ucts provide necessary antibody replacement, each 
has subtle differences and are thus not interchange-
able because switching from one brand to another is 
one of most common causes of side effects (10). 
Adverse reactions
Although all donors are required to undergo screen-
ing, there is possibility that late complications may 
occur, such as more severe infections, after taking 
blood before seroconversion (11).
Like any other form of treatment, the use of immuno-
globulins presumes a certain risk of adverse events 
and side effects. The side effects of IVIG treatment 
relate mainly to the dosage and rate of administra-
tion. Reactions are categorized as early and late re-
actions based on reaction times, while the criterion 
for the reaction onset mechanism leads to the two-
fold categorization, specifically immune-related and 
non-immunological. Early side effects occur within 
30-60 minutes after commencing administration 
(12,13), while Richter (2005) notes that hepatitis, 
HIV, meningoencephalitis are possible late reactions 
given that immunoglobulins are obtained from vari-
ous volunteer blood donors (11,14). Side effects may 
be mild, moderate or life-threatening depending on 
the clinical condition (Table 1). 
Table 1. Adverse Reaction to IVIG
MILD 





















Respiratory symptoms: Chest pain, 
clenching in the throat, a sense of lacking 
air, bronchospasm, saturation below 94%, 
rhinitis, dry cough, angioedema, harsh 
voice, stridor
Abdominal symptoms: Abdominal pain, 
cramps, diarrhea, nausea, vomiting
Circulatory: Hypotension, tachycardia, pale 
and damp skin
Other: Itching, redness of the skin on the 
neck, face and ears, watery eyes
* Immediate reaction—within six hours from onset of infusion
** Delayed reaction—six hours to one week after infusion
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ics of the medicine and administration protocol and 
evaluate the existence and passage of the venous 
pathway, as well as the condition (size, elasticity, 
position) of the child’s veins. IVIG are administered 
intravenously via an approved intravenous infusion 
pump. The American Academy of Allergy, Asthma and 
Immunology (AAAAI) strongly discourages the use of 
permanent indwelling ports or central venous lines 
in antibody deficient patients due to the risk of sys-
temic infection (sepsis) and thrombotic events (25).
If IVIG is stored in a refrigerator, it needs to be 
warmed to room temperature (8) for at least 30 
minutes before administration in order to minimize 
adverse effects. It must never be heated up in a mi-
crowave or in any other way as the protein may be-
come denatured (8). Importantly, vigorous mixing is 
prohibited. All products should be inspected for the 
presence of particulates before pooling, and products 
with broken seals should not be used.
Education and moral support for the child and par-
ents is very important. After a detailed medical 
history, physical examination and measurements 
Depending on the indication, doses are determined 
according to the child’s body weight and the labora-
tory findings pertaining to immunoglobulin. Therapy 
is repeated at regular intervals every 3 to 4 weeks 
(17), and it takes 3 to 6 months to achieve balance 
after the beginning of therapy.
The most common side effects are expected during 
the first administration of intravenous immunoglobu-
lins (21, 22). The rate of infusion is determined by 
ml/ kg per hour. Infusion rates are usually started at 
0.01–0.02 ml/kg/min and increased up to 0.1 ml/kg/
min (23).
Nursing interventions during first IVIG 
administration 
Intravenous immunoglobulins are administered to 
children under hospital conditions in a strictly con-
trolled environment, respecting all the rules for 
asepsis, and based on the physician’s written order. 
Nurses administer the majority of immunoglobulin, 
in 90% of the cases (18). Prior to each IVIG admin-
istration, the nurse must be familiar with the specif-
Table 2. Nursing interventions in case of unwanted reactions (18,19,21-24)
UNWANTED REACTIONS CAUSES NURSING INTERVENTIONS
MILD REACTION
First infusion
Infusion rate may be too fast
Solution is not at room 
temperature
Longer interval from prior 
infusion
Switch to a new product
Slow down the rate of administration or stop 
infusion for 15-30 minutes
If necessary, apply analgesic therapy
Assess pain on the pain scale
If headaches persist after 30 minutes, stop the 
infusion permanently
MODERATE REACTION
Infusion rate may be too fast
Solution is not at room 
temperature
Inflammatory response to 
specific product
No pre-infusion or post-
infusion hydration
Slow down the rate of administration or stop the 
infusion for 15-30 minutes
If the nausea does not stop after 30 minutes, stop 
the infusion
Administer antiemetics if necessary




The infusion should be stopped immediately. 
In case of anaphylactic reactions administer 
adrenaline according to a clearly defined protocol 
In line with ERC guidelines, adrenaline must be 
administered intramuscularly in the anteromedial 
part of the upper leg as it maximizes absorption. 
Use of intravenous adrenaline should be performed 
only by physicians who are trained in administering 
vasopressors.
Oxygenation and IV fluid replacement
Continuous patient monitoring is important
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during the three weeks following the last administra-
tion. Importantly, a child should be continually moni-
tored if the last dose was administered more than 6 
weeks ago (11), and if the infusion is administered 
from a new producer or if a higher dose is prescribed. 
For children, the best practice is not to change prod-
ucts once a particular brand has been commenced 
(14).
Nursing interventions after completing 
therapy
Physicians most frequently prescribe 0.9% NaCl infu-
sion to flushthe infusion line after the administration 
of immunoglobulin. If at the site of the intravenous 
cannula there is no redness, edema and other inflam-
mation signs, the cannula can be left until completing 
the observation. Conversely, the nurse must remove 
the cannula and treat the inflamed IV site according 
to the protocol provided by the institution. In this 
case, the cannula is to be placed in another position, 
preferably on the opposite extremity. The exact time 
of terminating infusion is noted in patient documen-
tation along with all vital baseline parameters and 
description of the child’s condition.
After the infusion administration, nurse must provide 
patient/family education before discharge, regarding 
symptom management and appropriate actions for 
symptom severity. It is also necessary to inform the 
patient about the next arrival date, respecting the 
protocol of the drug administration.
Psychological support for families
In comparison with healthy children and adults, pa-
tients with PID experience measurably lower general 
health along with higher hospitalization rates and 
restrictions to physical, school, and social activities 
(28).
When a child is diagnosed with PID, often each mem-
ber of the family has many questions. The whole 
family must come to terms with the illness and per-
haps make major changes in schedules and priorities. 
Parents are often faced with many challenges, dif-
ficulties and decisions that other parents will never 
have to face. 
One of the most important things for the whole fam-
ily is to provide accurate age-appropriate information 
and explain everything about the diagnosis, therapy 
and solutions. A child’s understanding of their PID 
of vital functions, the child is placed in a bed on a 
ward equipped with a central oxygen supply. Given 
that administration, depending on the dose, lasts for 
several hours, the child should be pleasantly accom-
modated and wear comfortable clothing prior to com-
mencing the treatment. Premedication is most often 
not necessary (8) but is usually given if there has 
been a recent adverse reaction (14).
Before using IVIG, it is necessary to check the correct-
ness of the drug packaging, the name and expiration 
date, manner of administering and the concentration 
based on the instructions and compare them with 
the physician’s written order. If the child is to receive 
a number of bottles, the starting time for administra-
tion and sequential position of the dose in the overall 
order of doses should be written on each bottle. To 
maintain records on the temperature list, the name 
and lot number of the drug should be documented, 
and the empty vials are to be kept for 24 hours after 
administering. 
When the drugs are administered, emergency equip-
ment including adrenalin (1:1000) must be readily 
available for life support purposes, and in case of an 
anaphylactic reaction (26).
Visual monitoring and baseline vital function moni-
toring is necessary during the first 30-60 minutes 
from commencing administration because most of 
the early side effects occur in that period. Subse-
quently, vital signs are measured every 60 minutes 
and this is obligatory before each new dose. All pa-
rameters in children should be constantly monitored 
and a skin examination for rash and urticaria should 
be performed periodically, as well as other symptoms 
and signs that may indicate unwanted reactions. Eve-
ry change in normal vital signs should be recorded. 
An adverse reaction to administered immunoglobu-
lin may also be related to infusion rate, and it is also 
important to comply with speed-related guidelines. 
A nurse records the intake and the amount of fluid, 
while encouraging the child to take as much fluid as 
possible to prevent renal complications (8,27).
Nursing interventions during recurrent 
infusion
Infusion of immunoglobulins is repeated at regular 
intervals every 3-4 weeks (8). During re-hospitaliza-
tion, information should also be collected on previous 
use, possible complications (fatigue, headaches, nau-
sea) and dosage toleration, including infection data 
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Ključne riječi: primarne imunodeficijencije, nadomjesna 
terapija, medicinska sestra
Sažetak
Primarne imunodeficijencije stanja su koja odlikuje 
povećana osjetljivost organizma na infekcije zbog 
nedostataka jedne ili više komponenti imunološkog 
sustava. Imunoglobulini su normalni sastavni dijelovi 
ljudskog tijela s glavnom ulogom u imunološkoj obra-
ni. Djeca koja boluju od primarne imunodeficijencije 
imaju ih malo ili ih uopće nemaju te kod njih cjelo-
životna nadomjesna terapija imunoglobulina (IgG) 
predstavlja jedini učinkovit tretman kao zlatni stan-
dard u liječenju primarnih imunodeficijencija. Svrha 
je takve terapije prevencija akutnih infekcija te sma-
njenje komplikacija nastalih kao posljedica infekcije. 
Medicinska sestra sa svojim znanjem i kompetenci-
jama neizostavna je spona u sigurnoj i kvalitetnoj 
primjeni imunoterapije, u pružanju neposredne psi-
hičke potpore djetetu i cijeloj obitelji te je upravo ona 
primjenjuje u 90 % slučajeva prema pisanoj odredbi 
liječnika.
Pregledom literature prikazane su spoznaje o percep-
ciji medicinskih sestara u vezi s terapijom imunoglo-
bulinima. Ovaj rad predstavlja smjernice medicinskim 
sestrama za skrb prije, tijekom i nakon primjene intra-
venskih imunoglobulina kod djece s primarnom bole-
šću imunodeficijencije.
NADOMJESNA TERAPIJA INTRAVENOZNIM IMUNOGLOBULINIMA  
KOD DJECE OBOLJELE OD PRIMARNE IMUNODEFICIJENCIJE: SESTRINSKE SMJERNICE
